ABSTRACT

Introduction

Ixekizumab (IXE) is a high affinity IgG4 approved for the treatment of ankylosing spondylitis (AS). Recently, two phase III randomized clinical trials (COAST-V, COAST-W) showed significant and sustained improvements in signs and symptoms of AS as evaluated by ASAS40 response. Areas covered: The authors performed a comprehensive literature search on this topic, by a review of published articles to date. The authors introduced the structure and the mechanism of action of IXE, and critically reviewed data from clinical trials, concerning its efficacy and safety in AS.Expert opinion: IXE proved dramatic efficacy and tolerable safety in patients with AS, in particular, patients with intolerance or insufficient response to TNFi, which provides an alternative and breakthrough for the treatment options of AS. IXE might not work in AS with IBD and uveitis involvement. Patients treated with IXE should be aware of candida infection in long term application.

中文翻译：

---

Ixekizumab 用于治疗强直性脊柱炎。

摘要

介绍

Ixekizumab (IXE) 是一种高亲和力 IgG4，被批准用于治疗强直性脊柱炎 (AS)。最近，根据 ASAS40 反应评估，两项 III 期随机临床试验（COAST-V、COAST-W）显示 AS 的体征和症状有显着和持续的改善。涵盖的领域：作者通过对迄今为止已发表文章的审查，对该主题进行了全面的文献检索。作者介绍了 IXE 的结构和作用机制，并严格审查了临床试验中关于其在 AS 中的有效性和安全性的数据。专家意见：IXE 在 AS 患者中证明了显着的疗效和可耐受的安全性，特别是对 TNFi 不耐受或反应不足的患者，这为 AS 的治疗选择提供了替代和突破。IXE 可能不适用于患有 IBD 和葡萄膜炎的 AS。接受 IXE 治疗的患者应注意长期应用中的念珠菌感染。